Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Finerenone). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Kanopas 10 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended starting dosage: 10 mg or 20 mg orally once daily based on estimated glomerular filtration rate (eGFR) and serum potassium thresholds. Increase dosage after 4 weeks to the target dose of 20 mg once daily, based on eGFR and serum potassium thresholds. Tablets may be taken with or without food.Recommended Dosage- eGFR ≥60 mL/min/1.73 m2: starting dose 20 mg once daily eGFR ≥25 to <60 mL/min/1.73 m2: starting dose 10 mg once daily eGFR <25 mL/min/1.73 m2: not recommended For patients who are unable to swallow whole tablets, Finerenone may be crushed and mixed with water or soft foods.Monitoring and Dose Adjustment: The target daily dose of Finerenone is 20 mg. Measure serum potassium 4 weeks after initiating treatment and adjust dose (see Table 2); if serum potassium levels are > 4.8 to 5.0 mEq/L, initiation of Finerenone treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels. Monitor serum potassium 4 weeks after a dose adjustment and throughout treatment and adjust the dose as needed.Missed doses: Direct a patient to take a missed dose as soon as possible after it is noticed, but only on the same day. If this is not possible, the patient should skip the dose and continue with the next dose as prescribed.
Side Effects
Adverse reactions occurring in ≥ 1% of patients on Finera and more frequently than placebo are hyperkalemia, hypotension, and hyponatremia.
Cautions & Contraindications
Warnings & Precautions
Finera can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with Finera and dose accordingly. Do not initiate Finera if serum potassium is > 5.0 mEq/L. Measure serum potassium periodically during treatment with Finera and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium.
Contraindications
Contraindicated in concomitant use with strong CYP3A4 inhibitors & patients with adrenal insufficiency.